Endometrial Cancer | Cases from the Community: Investigators Discuss Available Research Guiding the Care of Patients with Endometrial Cancer

Featuring perspectives from Drs Robert L Coleman, Matthew A Powell and Brian M Slomovitz, moderated by Dr Shannon N Westin, including the following topics:

• Immune Checkpoint Inhibitors for Patients with Advanced Microsatellite Instability (MSI)-High/Mismatch Repair (MMR)-Deficient Endometrial Cancer — Dr Powell
  • Introduction (0:00)
  • Case: A woman in her early 60s with MSI-high recurrent endometrioid adenocarcinoma of the uterus experiences progression after minimal response to carboplatin/paclitaxel — Lyndsay J Willmott, MD (2:25)
  • Case: A woman in her early 50s with MSI-high metastatic endometrial adenocarcinoma after rapid, highly symptomatic progressive disease on paclitaxel/carboplatin — Kellie E Schneider, MD (8:21)
  • Faculty presentation: Dr Powell (14:35)
• Immunotherapy-Based Strategies for Patients with MMR-Proficient (pMMR) Endometrial Cancer — Dr Coleman
  • Case: A woman in her early 60s with a 10-cm right ovarian mass and right pelvic adenopathy; total abdominal hysterectomy with bilateral salpingo-oophorectomy and para-aortic lymph node dissection reveal microsatellite stable (MSS) carcinosarcoma of the endometrium with right ovary and pelvic lymph node involvement (R0); adjuvant paclitaxel/carboplatin administered — Thomas P Morrissey, MD (24:46)
  • Case: A woman in her late 60s with Stage IB, Grade 1 endometrial cancer after hysterectomy/sentinel lymph node biopsy — Dana M Chase, MD (30:11)
  • Faculty presentation: Dr Coleman (35:54)
• Diagnosis and Management of Adverse Events Associated with Immune Checkpoint Inhibitors Alone and in Combination for Endometrial Cancer — Dr Westin
  • Case: A woman in her early 60s with a family history of breast cancer — Dr Morrissey (46:05)
  • Case: A woman in her mid 70s who underwent hysterectomy, lymphadenectomy, omentectomy and 6 cycles of carboplatin/paclitaxel for a Stage IB MSS serous endometrial cancer; develops metastatic disease to the lungs 11 months later and is started on lenvatinib/pembrolizumab — Dr Chase (51:36)
  • Faculty presentation: Dr Westin (57:09)
• Novel Investigational Agents and Strategies Under Evaluation for Patients with Endometrial Cancer — Dr Slomovitz
  • Case: A woman in her early 70s with HER2-positive serous carcinoma of the uterus receives adjuvant carboplatin/paclitaxel and trastuzumab, now no evidence of disease and receiving maintenance trastuzumab — Dr Willmott (1:07:34)
  • Case: A woman in her early 80s with MSI-high metastatic endometrial cancer who receives talazoparib on the TAPUR clinical trial after experiencing progressive disease on pembrolizumab after 4 cycles — John K Chan, MD (1:13:01)
  • Faculty presentation: Dr Slomovitz (1:18:53)

CME information and select publications